Developer docs
API playgroundTry for free, no card

Search company profiles

Distalmotion

Full company profile

uuid00004as

Namestring
Distalmotion
Legal namestring
Distalmotion SA
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Distalmotion SA is a Swiss medical device company founded in 2012 as a spin-off from the EPFL Robotics Lab in Lausanne, headquartered in Epalinges, Switzerland with approximately 150 employees representing over 25 nationalities. The company develops and commercializes the DEXTER Robotic Surgery System, a compact, mobile soft-tissue surgical robot purpose-built for the ambulatory surgery center (ASC) and outpatient hospital market where conventional robotic platforms face adoption barriers around footprint, cost, and workflow. The system consists of a sterile surgeon console (DEXTER L6), mobile patient carts, an open-architecture endoscope arm compatible with all 5–10mm endoscopes (including 4K fluorescence), and a suite of single-use fully wristed instruments; key technical differentiators include a ~4-minute setup time, a 125 sq ft footprint, sterile console that keeps the surgeon within the sterile field, and a hybrid modality allowing seamless switching between robotic and laparoscopic approaches without redocking.

The company's revenue model centers on capital equipment sales of the DEXTER system to hospitals and ASCs, complemented by recurring service and support (including per-procedure clinical specialist coverage) and training services delivered through Dexter Academy. Pricing is quote-based with multi-year contracts and tailored financing solutions; specific ASP is not publicly disclosed but typical surgical robot ASPs run $1M+. Distribution is direct via enterprise field sales, targeting US ASC networks and multi-site hospital systems. Commercial momentum is building through high-profile accounts including AdventHealth (first multi-system US deployment across its 50-hospital network), HonorHealth-affiliated ASCs, SCA, Surgery Partners, and Cypress Surgery Center, with over 3,000 patients treated across 30+ procedure types by 100+ surgeons in Europe and the US.

The company has cumulatively raised over $390 million across multiple late-stage venture rounds (Series E $90M in January 2022, Series F $150M first close in April 2023, Series G $150M in November 2025) led by Revival Healthcare Capital, with a strategic investment from Johnson & Johnson Innovation (JJDC) in January 2026. Distalmotion holds CE mark since 2020 across urology, gynecology, and general surgery, and four FDA 510(k) clearances including a June 2026 clearance for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection procedures, with authorization to begin a US myomectomy clinical trial.

Short descriptiontext

Distalmotion SA is a Swiss medical device company developing the DEXTER compact soft-tissue surgical robot for ASCs and outpatient hospitals, selling capital equipment, service, and training directly to US hospital networks and ambulatory surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEpalinges, Switzerland
HQ citystring
Epalinges
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
surgical robotics, robotic surgery systems, minimally invasive surgery, ambulatory surgical care, medical device manufacturing
Industry4 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Surgical Robotics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1DEXTER Surgical Robot System Sales
TypeHardware Sales
Description

Sale of the DEXTER robotic surgery system to hospitals and ambulatory surgery centers. The company provides flexible, cost-effective financing options to make the system economically accessible. Revenue from initial capital equipment sale with potential for service and support contracts.

distalmotion.com
2Service and Support
TypeProfessional Services
Description

Ongoing customer service and support including expert clinical specialists providing case support in every procedure alongside surgical teams as they progress up the learning curve.

distalmotion.com
3Training Services (Dexter Academy)
TypeProfessional Services
Description

State-of-the-art training curriculum for surgeons and surgical teams delivered through Dexter Academy to reach Dexter proficiency, including e-learning, simulator training, and hands-on training sessions.

distalmotion.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Custom financing solutions for hospitals and ASCs
ModelOtherBilling cadenceMulti-year contract
Notes

Flexible, tailored, cost-effective financing options available. No specific pricing publicly disclosed - requires contact with sales team.

distalmotion.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1DEXTER
Description

DEXTER is a soft tissue surgical robot system designed to simplify robotic surgery operations, enabling more surgeons in more operating rooms to provide robotic surgery benefits to more patients.

distalmotion.com
Core offering1 text field

Distalmotion develops, manufactures, and sells the DEXTER Robotic Surgery System, a compact and mobile soft tissue surgical robot that integrates into any operating room without structural modifications. The system comprises a sterile surgeon console, mobile patient carts, an open-architecture endoscope arm, and a suite of single-use fully wristed instruments, and is purpose-built for outpatient/ambulatory settings as well as hospital general surgery, gynecology, and urology use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Setup time under 4 minutes vs competitors requiring significantly more time
+4 more records
Product overview1 text field

Distalmotion offers the DEXTER® Robotic Surgery System as its primary product—a small, mobile surgical robot designed for soft tissue procedures in general surgery, urology, and gynecology. The system consists of the L6 Surgeon Console, L6 Patient Carts, an open architecture endoscope arm, and a suite of fully wristed single-use instruments. Supporting the core product is Dexter Academy, a comprehensive training program that includes e-learning modules, simulator training, and hands-on training sessions for surgeons and nurses. The company holds multiple trademarks including DEXTER - THE SURGEONS ROBOT™ and DEXTER ON-DEMAND ROBOTICS™. DEXTER is CE marked for Europe and FDA cleared for specific procedures in the US, particularly targeting the Ambulatory Surgery Center market.

Product and service2 records
1DEXTER Robotic Surgery System
CategorySurgical Robotics
Description

A small, mobile, soft-tissue surgical robot system designed to integrate into any operating room without infrastructure modifications. Features a sterile surgeon console, open architecture compatible with existing instrumentation, ~4 minute setup time, hybrid robotic/laparoscopic capability, and a suite of single-use fully wristed instruments. Sold to hospitals and ambulatory surgery centers for general surgery, urology, and gynecology procedures.

2Dexter Academy
CategoryMedical Training Services
Description

State-of-the-art training curriculum developed with expert teaching centers and clinicians that equips surgeons and surgical teams with the knowledge and skills to reach DEXTER proficiency. Includes e-learning modules, simulator training, and hands-on training sessions. Sold as part of the customer onboarding and adoption program for hospitals, ASCs, and surgical teams.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

First multi-system sale in US market. AdventHealth, operating 50 hospitals across nine states, purchased DEXTER system for deployment across hospital network. Completed first cases as part of effort to expand robotic surgery in outpatient departments.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Distalmotion founded in 2012 as spin-off from EPFL Robotics Lab. Company developed DEXTER in collaboration with expert teaching centers and clinicians. EPFL Innogrant program contributed to company founding.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

ASCs affiliated with HonorHealth adopting DEXTER system as part of commercial expansion in US outpatient surgery market.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

ASC network adopting DEXTER system as part of growing commercial momentum in US outpatient surgery center market.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

ASC network adopting DEXTER system for outpatient surgical procedures in US market expansion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant incumbent in robotic-assisted surgery with the da Vinci platform, controlling the majority of the global installed base in soft tissue robotics. Directly competes with DEXTER in general surgery, urology, and gynecology, but its systems are larger, more expensive, and hospital-centric.

TypeDirect peer
Description

UK-based developer of the Versius surgical robotic system, a small, modular soft tissue robot positioned similarly to DEXTER for general surgery, gynecology, and urology. Direct competitor targeting cost-constrained settings and ambulatory care, with overlapping FDA/CE regulatory pathway.

TypeDirect peer
Description

French-American surgical robotics company developing a compact, versatile soft tissue robotic platform also aimed at expanding robotic surgery access to outpatient and ambulatory settings. Direct competitor to DEXTER in the small-footprint robotic surgery niche.

TypeBroad incumbent
Description

Global medtech incumbent that launched the Hugo RAS system, a modular robotic-assisted surgery platform for urology, gynecology, and general surgery. Competes broadly in the same surgical robotics category as DEXTER but as part of a much larger portfolio.

5Johnson & Johnson
TypeBroad incumbent
Description

Major medtech incumbent developing its own soft tissue surgical robotics platform (Ottava) and the Monarch endoluminal system. Both a strategic investor in Distalmotion (via JJDC) and a competitor with overlapping product roadmaps.

TypeDirect peer
Description

Developer of the Senhance surgical system, a digital laparoscopy platform with robotic-like features targeting general surgery, gynecology, and urology. Direct competitor in the soft tissue minimally invasive surgical robotics space, with a more cost-sensitive positioning similar to DEXTER.

TypeEmerging player
Description

Emerging surgical robotics company developing a single-port robotic system for abdominal procedures. Earlier-stage than Distalmotion, with partial overlap in soft tissue robotics and a similar focus on improving access and reducing footprint.

TypeBroad incumbent
Description

Major medtech incumbent with the Mako robotic platform in orthopedics. While focused on a different surgical specialty (orthopedics), Stryker represents a broader competitive model of incumbent surgical robotics expansion that could eventually encroach on DEXTER's indications.

TypeEmerging player
Description

Emerging surgical intelligence and robotics company focused on intraoperative visualization and AI-assisted surgery. Partial overlap with DEXTER's surgical workflow enhancement value proposition, but more focused on software/AI than full robotic platforms.

TypeOthers
Description

UK-based engineering company with surgical robotics and neurosurgical navigation products. Adjacent player in surgical robotics but focused primarily on neurological and stereotactic procedures rather than the soft tissue general surgery market where DEXTER competes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Distalmotion

Surgical Roboticsdistalmotion.com

Distalmotion SA is a Swiss medical device company developing the DEXTER compact soft-tissue surgical robot for ASCs and outpatient hospitals, selling capital equipment, service, and training directly to US hospital networks and ambulatory surgery centers.

What Distalmotion does

Distalmotion SA is a Swiss medical device company founded in 2012 as a spin-off from the EPFL Robotics Lab in Lausanne, headquartered in Epalinges, Switzerland with approximately 150 employees representing over 25 nationalities. The company develops and commercializes the DEXTER Robotic Surgery System, a compact, mobile soft-tissue surgical robot purpose-built for the ambulatory surgery center (ASC) and outpatient hospital market where conventional robotic platforms face adoption barriers around footprint, cost, and workflow. The system consists of a sterile surgeon console (DEXTER L6), mobile patient carts, an open-architecture endoscope arm compatible with all 5–10mm endoscopes (including 4K fluorescence), and a suite of single-use fully wristed instruments; key technical differentiators include a ~4-minute setup time, a 125 sq ft footprint, sterile console that keeps the surgeon within the sterile field, and a hybrid modality allowing seamless switching between robotic and laparoscopic approaches without redocking.

The company's revenue model centers on capital equipment sales of the DEXTER system to hospitals and ASCs, complemented by recurring service and support (including per-procedure clinical specialist coverage) and training services delivered through Dexter Academy. Pricing is quote-based with multi-year contracts and tailored financing solutions; specific ASP is not publicly disclosed but typical surgical robot ASPs run $1M+. Distribution is direct via enterprise field sales, targeting US ASC networks and multi-site hospital systems. Commercial momentum is building through high-profile accounts including AdventHealth (first multi-system US deployment across its 50-hospital network), HonorHealth-affiliated ASCs, SCA, Surgery Partners, and Cypress Surgery Center, with over 3,000 patients treated across 30+ procedure types by 100+ surgeons in Europe and the US.

The company has cumulatively raised over $390 million across multiple late-stage venture rounds (Series E $90M in January 2022, Series F $150M first close in April 2023, Series G $150M in November 2025) led by Revival Healthcare Capital, with a strategic investment from Johnson & Johnson Innovation (JJDC) in January 2026. Distalmotion holds CE mark since 2020 across urology, gynecology, and general surgery, and four FDA 510(k) clearances including a June 2026 clearance for sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection procedures, with authorization to begin a US myomectomy clinical trial.

Distalmotion firmographics

Firmographics
Name
Distalmotion
Legal name
Distalmotion SA
Website
https://distalmotion.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Distalmotion SA is a Swiss medical device company developing the DEXTER compact soft-tissue surgical robot for ASCs and outpatient hospitals, selling capital equipment, service, and training directly to US hospital networks and ambulatory surgery centers.
Ownership category
akta.pro rank

Distalmotion industry classification

Industry
Product category
Surgical Robotics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAOAF
Endourology & Minimally Invasive Urologic Surgery

Keywords

  • Surgical robotics
  • Robotic surgery systems
  • Minimally invasive surgery
  • Ambulatory surgical care
  • Medical device manufacturing

Where Distalmotion is headquartered

Location

Headquarters

HQ city
Epalinges
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Distalmotion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. DEXTER Surgical Robot System Sales: Sale of the DEXTER robotic surgery system to hospitals and ambulatory surgery centers. The company provides flexible, cost-effective financing options to make the system economically accessible. Revenue from initial capital equipment sale with potential for service and support contracts.
  2. Service and Support: Ongoing customer service and support including expert clinical specialists providing case support in every procedure alongside surgical teams as they progress up the learning curve.
  3. Training Services (Dexter Academy): State-of-the-art training curriculum for surgeons and surgical teams delivered through Dexter Academy to reach Dexter proficiency, including e-learning, simulator training, and hands-on training sessions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom financing solutions for hospitals and ASCs

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Distalmotion product offering

Product offering

Core offering

Distalmotion develops, manufactures, and sells the DEXTER Robotic Surgery System, a compact and mobile soft tissue surgical robot that integrates into any operating room without structural modifications. The system comprises a sterile surgeon console, mobile patient carts, an open-architecture endoscope arm, and a suite of single-use fully wristed instruments, and is purpose-built for outpatient/ambulatory settings as well as hospital general surgery, gynecology, and urology use.

Product overview

Distalmotion offers the DEXTER® Robotic Surgery System as its primary product—a small, mobile surgical robot designed for soft tissue procedures in general surgery, urology, and gynecology. The system consists of the L6 Surgeon Console, L6 Patient Carts, an open architecture endoscope arm, and a suite of fully wristed single-use instruments. Supporting the core product is Dexter Academy, a comprehensive training program that includes e-learning modules, simulator training, and hands-on training sessions for surgeons and nurses. The company holds multiple trademarks including DEXTER - THE SURGEONS ROBOT™ and DEXTER ON-DEMAND ROBOTICS™. DEXTER is CE marked for Europe and FDA cleared for specific procedures in the US, particularly targeting the Ambulatory Surgery Center market.

Differentiator

Problem solved

Functional benefit

Brands

  • DEXTER: DEXTER is a soft tissue surgical robot system designed to simplify robotic surgery operations, enabling more surgeons in more operating rooms to provide robotic surgery benefits to more patients.

Products and services

  • DEXTER Robotic Surgery System A small, mobile, soft-tissue surgical robot system designed to integrate into any operating room without infrastructure modifications. Features a sterile surgeon console, open architecture compatible with existing instrumentation, ~4 minute setup time, hybrid robotic/laparoscopic capability, and a suite of single-use fully wristed instruments. Sold to hospitals and ambulatory surgery centers for general surgery, urology, and gynecology procedures.
  • Dexter Academy State-of-the-art training curriculum developed with expert teaching centers and clinicians that equips surgeons and surgical teams with the knowledge and skills to reach DEXTER proficiency. Includes e-learning modules, simulator training, and hands-on training sessions. Sold as part of the customer onboarding and adoption program for hospitals, ASCs, and surgical teams.

Quantifiable outcome

  • Setup time under 4 minutes vs competitors requiring significantly more time
  • +4 more outcomes

Companies that use Distalmotion

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Distalmotion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Distalmotion partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and major.

  • AdventHealthflagshipStrategic or Co-development PartnerFirst multi-system sale in US market. AdventHealth, operating 50 hospitals across nine states, purchased DEXTER system for deployment across hospital network. Completed first cases as part of effort to expand robotic surgery in outpatient departments.
  • EPFL (Swiss Federal Institute of Technology Lausanne)coreStrategic or Co-development PartnerDistalmotion founded in 2012 as spin-off from EPFL Robotics Lab. Company developed DEXTER in collaboration with expert teaching centers and clinicians. EPFL Innogrant program contributed to company founding.
  • HonorHealthmajorStrategic or Co-development PartnerASCs affiliated with HonorHealth adopting DEXTER system as part of commercial expansion in US outpatient surgery market.
  • SCA (Surgical Care Affiliates)majorStrategic or Co-development PartnerASC network adopting DEXTER system as part of growing commercial momentum in US outpatient surgery center market.
  • Surgery PartnersmajorStrategic or Co-development PartnerASC network adopting DEXTER system for outpatient surgical procedures in US market expansion.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Distalmotion competitors and assessment

Company assessment

Broad incumbents

  • Intuitive Surgical: Dominant incumbent in robotic-assisted surgery with the da Vinci platform, controlling the majority of the global installed base in soft tissue robotics. Directly competes with DEXTER in general surgery, urology, and gynecology, but its systems are larger, more expensive, and hospital-centric.
  • Medtronic: Global medtech incumbent that launched the Hugo RAS system, a modular robotic-assisted surgery platform for urology, gynecology, and general surgery. Competes broadly in the same surgical robotics category as DEXTER but as part of a much larger portfolio.
  • Johnson & Johnson: Major medtech incumbent developing its own soft tissue surgical robotics platform (Ottava) and the Monarch endoluminal system. Both a strategic investor in Distalmotion (via JJDC) and a competitor with overlapping product roadmaps.
  • Stryker: Major medtech incumbent with the Mako robotic platform in orthopedics. While focused on a different surgical specialty (orthopedics), Stryker represents a broader competitive model of incumbent surgical robotics expansion that could eventually encroach on DEXTER's indications.

Direct peers

  • CMR Surgical: UK-based developer of the Versius surgical robotic system, a small, modular soft tissue robot positioned similarly to DEXTER for general surgery, gynecology, and urology. Direct competitor targeting cost-constrained settings and ambulatory care, with overlapping FDA/CE regulatory pathway.
  • Moon Surgical: French-American surgical robotics company developing a compact, versatile soft tissue robotic platform also aimed at expanding robotic surgery access to outpatient and ambulatory settings. Direct competitor to DEXTER in the small-footprint robotic surgery niche.
  • Asensus Surgical: Developer of the Senhance surgical system, a digital laparoscopy platform with robotic-like features targeting general surgery, gynecology, and urology. Direct competitor in the soft tissue minimally invasive surgical robotics space, with a more cost-sensitive positioning similar to DEXTER.

Emerging players

  • Vicarious Surgical: Emerging surgical robotics company developing a single-port robotic system for abdominal procedures. Earlier-stage than Distalmotion, with partial overlap in soft tissue robotics and a similar focus on improving access and reducing footprint.
  • Activ Surgical: Emerging surgical intelligence and robotics company focused on intraoperative visualization and AI-assisted surgery. Partial overlap with DEXTER's surgical workflow enhancement value proposition, but more focused on software/AI than full robotic platforms.

Others

  • Renishaw: UK-based engineering company with surgical robotics and neurosurgical navigation products. Adjacent player in surgical robotics but focused primarily on neurological and stereotactic procedures rather than the soft tissue general surgery market where DEXTER competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Distalmotion social profiles

Digital presence

Distalmotion compliance and trust

Trust signal

Compliance5 records

Distalmotion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Distalmotion leadership team

Management profile

Number of profiles

Profiles5 records

Distalmotion funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Distalmotion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Distalmotion

What does Distalmotion do?

Distalmotion develops, manufactures, and sells the DEXTER Robotic Surgery System, a compact and mobile soft tissue surgical robot that integrates into any operating room without structural modifications. The system comprises a sterile surgeon console, mobile patient carts, an open-architecture endoscope arm, and a suite of single-use fully wristed instruments, and is purpose-built for outpatient/ambulatory settings as well as hospital general surgery, gynecology, and urology use.

Is Distalmotion a public or private company?

Distalmotion is a private company. It is classified as venture growth investor backed and is currently operating.

When was Distalmotion founded?

Distalmotion was founded in 2012. It employs 101 to 250 people.

Where is Distalmotion based?

Distalmotion is headquartered in Epalinges, Switzerland, in the Europe region.

How does Distalmotion make money?

Three revenue lines are on record. DEXTER Surgical Robot System Sales are the primary driver. The others are service and Support and training Services (Dexter Academy).

Who are Distalmotion's main competitors?

Broad incumbents on record are Intuitive Surgical, Medtronic, Johnson & Johnson and Stryker. Direct peers are CMR Surgical, Moon Surgical and Asensus Surgical. Emerging players are Vicarious Surgical and Activ Surgical. Renishaw is listed as an others.

Does Distalmotion have an API?

No public API is recorded for Distalmotion.

What industry is Distalmotion in?

Distalmotion's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HDAAAIAC, Healthcare & Assistive Robotics. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chUp to $ 70M Term Loan Facility to boost Distalmotion US ASC ExpansionDistalmotion entered a senior secured term loan facility of up to $70 million with Perceptive Advisors. The financing supports its US ambulatory surgery center expansion and development of the DEXTER robotic surgery system. DEXTER is cleared for top four highest-volume soft tissue outpatient procedures.Startup ResearcherDistalmotion Secures Up to $70 Million Venture Debt from Perceptive AdvisorsDistalmotion secured up to $70 million in venture debt from Perceptive Advisors on Oct. 21, 2026, to support its DEXTER robotic surgery system in US ambulatory surgery centers. The capital will strengthen commercial presence and advance the DEXTER platform, which is cleared for top four soft tissue procedures.Business & FinancialDistalmotion Secures Up To $70 Million Term Loan Facility From Perceptive Advisors To Accelerate US ASC ExpansionDistalmotion secured a term loan facility of up to $70 million from Perceptive Advisors to accelerate its US ambulatory surgery center expansion. The financing supports continued DEXTER robotic surgery system adoption and development. DEXTER is cleared for top four soft tissue procedures in the US.startupticker.chTwo medtechs advance with regulatory approvalsSpineart received FDA approval for its cervical disc replacement system, expanding access to a motion-preserving surgical option in the United States. Simultaneously, Distalmotion obtained FDA clearance for its DEXTER robotic surgery system to perform ventral hernia repairs, completing its core outpatient portfolio.YahooDistalmotion receives FDA 510(k) clearance for Dexter robotic systemDistalmotion has received 510(k) clearance from the US Food and Drug Administration for its Dexter robotic surgery system to be used in ventral hernia repairs. This approval expands the device's authorized applications in the US to include four high-volume ambulatory procedures, joining its existing CE marking for use in Europe since 2022. The company highlights that these procedures account for over three million cases annually, with a significant portion performed in ambulatory settings.Medical Device NetworkDistalmotion receives FDA 510(k) clearance for Dexter robotic systemDistalmotion received 510(k) clearance from the US Food and Drug Administration for its Dexter robotic surgery system to be used in ventral hernia repairs. This approval allows the device to be utilized in four of the highest-volume soft tissue ambulatory procedures in the United States, bringing its total cleared indications to include hysterectomy, cholecystectomy, and inguinal hernia repair. The move marks a strategic milestone for Distalmotion by expanding its market presence in the US outpatient surgical sector.GlobeNewswireDistalmotion Expands its DEXTER® US Procedural Portfolio to the Top Four Ambulatory Procedures with FDA 510(k) Clearance for Ventral Hernia RepairDistalmotion received FDA 510(k) clearance for ventral hernia repair with its DEXTER robotic system, supported by the RAVEN study. The clearance enables use in the top four ambulatory procedures, including ventral hernia repair with over 600,000 annual cases. The company says this completes its core outpatient portfolio.startupticker.chThree Swiss medtechs expand regulatory clearances for surgical devicesThree Swiss medtech companies—Distalmotion, LEM Surgical, and CustomSurg—have each secured new regulatory clearances for their surgical devices. Distalmotion received FDA 510(k) clearance for four additional gynecological procedures with its DEXTER robotic surgery system, while LEM Surgical obtained its second FDA clearance for the Dynamis spine surgery robot. CustomSurg, an ETH Zurich spin-off, gained CE certification for its OrthoPlanner pre-operative fracture-planning platform, clearing it for the European market including the UK and Switzerland.Medical Device NetworkDistalmotion secures second FDA gynaecology clearance for DEXTER systemSwiss medical device company Distalmotion has received FDA 510(k) clearance for its DEXTER robotic surgery system, covering sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection procedures. The authorization marks the DEXTER system's second FDA clearance relating to gynaecology and fourth overall in the US, enabling providers at ambulatory surgery centres to broaden their gynaecological surgery portfolios. The company is also progressing with its US investigational device exemption study evaluating DEXTER in myomectomy, with over 4,000 patients already treated using the system.MassDeviceDistalmotion gets FDA nod to expand Dexter surgical robot indications to gynecologyDistalmotion announced FDA 510(k) clearance for its Dexter surgical robot to expand indications to sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection procedures. This marks the second FDA clearance for Dexter in gynecology and the system's fourth overall clearance, following previous indications for hysterectomy, salpingo-oophorectomy, and general surgery procedures. The company submitted for these latest indications approximately two months ago and continues advancing its clinical pipeline with an ongoing FDA investigational device exemption study for myomectomy.